Yes. Syphilis can infect the eye at any stage, and ocular syphilis is rising in the United States alongside overall syphilis rates. The bacterium Treponema pallidum reaches the eye through the bloodstream and can inflame nearly every structure, from the eyelid to the optic nerve. Untreated, it can cause permanent blindness. (CDC)

How the spirochete reaches the eye

Treponema pallidum is a spiral-shaped bacterium roughly 6 to 15 micrometers long and about 0.1 to 0.2 micrometers wide. That slenderness lets it corkscrew through tissue barriers that stop most bacteria. Within days to weeks of mucosal infection, the organism enters the bloodstream and disseminates widely, well before the first visible sore appears.

The eye is vulnerable because it is an immune-privileged site. Its internal compartments are walled off from normal immune surveillance by the blood-retina barrier and blood-aqueous barrier. Those barriers protect delicate visual tissue from inflammatory damage, but they also shelter the spirochete from circulating antibodies and immune cells. The eye becomes an accidental reservoir.

Which structures get hit depends on where the bacteria lodge. The organism can seed the conjunctiva, the sclera (the white outer wall), the cornea, the iris and ciliary body, the vitreous gel, the retina, the choroid (the vascular layer behind the retina), and the optic nerve. The resulting pattern is not one disease but a family of inflammations. Syphilitic uveitis, inflammation of the uveal tract, is the most common presentation. In practical terms, syphilis is a master impersonator inside the eye, producing inflammation that mimics many other conditions.

Quantified context: how common, and who is affected

Syphilis rates in the United States climbed sharply over the past two decades. Primary and secondary syphilis cases rose from about 6,000 in 2001 to more than 59,000 in 2022, though the increase slowed in 2023. Congenital syphilis, passed from mother to fetus, exceeded 3,700 cases in 2023, its highest count in decades. (CDC)

Ocular involvement is a recognized complication at every stage, not just late disease. Estimates of how often eye involvement occurs vary widely by population and era, so treat any single percentage with caution. The clinical literature consistently describes ocular syphilis as uncommon but not rare, and increasingly reported during the recent resurgence.

Certain groups carry disproportionate risk. Men who have sex with men account for a large share of adult cases, particularly those with HIV coinfection. People living with HIV may develop ocular syphilis at higher rates and with more rapid progression. Pregnant people transmit the infection to the fetus at high rates in untreated early syphilis, and the resulting congenital infection can damage the eyes along with other organs.

A timeline of ocular involvement

Stage of infection Typical timing after exposure Eye findings
Primary 10–90 days Rare; chancre on eyelid or conjunctiva possible
Secondary 2–12 weeks after primary lesion Most common stage for uveitis, optic neuritis, retinitis
Early latent Under 1 year, no symptoms Usually silent; eye involvement uncommon but reported
Late latent Over 1 year, no symptoms Rare eye involvement without other organ disease
Tertiary (neurosyphilis) Years to decades Optic atrophy, Argyll Robertson pupil, cranial nerve palsies
Congenital Present at birth or early childhood Interstitial keratitis, chorioretinitis, optic nerve disease, "salt-and-pepper" retina

The table reflects classic teaching, but real cases defy tidy staging. Ocular syphilis can appear as the first sign of infection, before any chancre or rash, and it can recur months or years after apparently adequate treatment of early syphilis. A patient with no remembered symptoms and a clear history is still a candidate. The stage at which eye disease appears does not reliably predict how severe it will be.

The mechanisms: why syphilis damages vision

The bacterium itself does not secrete a classic toxin. Damage comes from two interacting forces: direct tissue invasion and the immune response it provokes. The spirochete attaches to host cells and to the inner walls of small blood vessels, causing endarteritis, inflammation of the vessel lining. This narrows and injures blood vessels that supply the retina, choroid, and optic nerve.

That vascular injury explains several signature patterns. Syphilitic retinitis often produces fluffy white patches in the retina with accompanying inflammation of the overlying vitreous. The choroid, a densely vascular layer, can develop pale lesions called placoid patches when its vessels are compromised. Optic neuritis arises when the optic nerve becomes inflamed, threatening vision loss fast. Interstitial keratitis, a classic congenital finding, is inflammation of the corneal stroma driven by the immune response to spirochetes embedded there.

The immune-privileged status of the eye adds a second layer. Because circulating antibodies do not patrol the eye's interior efficiently, the local immune system must mount its own response. That response is often exuberant and poorly regulated, causing collateral damage to retinal tissue. The eye may also become a hiding place where organisms persist despite treatment elsewhere. This is one reason ocular syphilis can recur after what seemed like adequate therapy. In plain terms, the bacterium damages the eye's blood vessels and triggers an overzealous local immune attack, and the eye's protective walls let the infection persist.

Misconceptions and the professional caveat

One common belief is that ocular syphilis only happens in late-stage disease. In reality, most reported cases present during secondary or early infection. Another is that a normal external eye exam rules out ocular syphilis. Because the inflammation is usually inside the eye, the disease is invisible without a slit-lamp exam and dilated retinal evaluation.

A third error is assuming a negative blood test settles the question. Serologic tests are the mainstay of diagnosis, but they can be negative in very early infection or misinterpreted in certain settings. Ophthalmologists are taught to test for syphilis in essentially every patient with unexplained uveitis, because the disease is treatable and the consequences of missing it are severe.

The professional caveat deserves emphasis. Ocular syphilis is a form of neurosyphilis by current clinical convention, regardless of whether the cerebrospinal fluid shows inflammation, and it is managed accordingly in specialist care. Yet the diagnosis rests on combining serology, eye exam, and increasingly imaging such as optical coherence tomography, which shows retinal and choroidal changes in fine detail. No single test confirms it in every case. A clinician who relies on one abnormal result or one normal result is likely to be misled. This is the counterintuitive detail: treating the eye as a simple extension of the bloodstream misses the disease's ability to hide inside the eye's privileged compartments.

Red-flag warnings

Sudden or progressive vision loss, especially in one eye, with or without pain. Floaters, flashing lights, or a gray veil in the visual field. Eye redness with pain and light sensitivity that does not resolve in a few days. Eye symptoms in anyone with a new rash, genital sore, or known syphilis exposure. Eye symptoms in a pregnant person, or in a newborn with a rash or jaundice. Uveitis that recurs after treatment or fails to respond to standard steroid therapy.

Any of these warrants prompt evaluation by an eye care professional and a syphilis blood test.

Practical actions and thresholds

The threshold for testing is low by design. A patient with uveitis of unclear cause should have syphilis serology, usually a treponemal-specific test (such as an enzyme immunoassay) confirmed by a nontreponemal test (such as RPR), or the reverse sequence depending on local practice. The two test types answer different questions: treponemal tests detect antibodies specific to the organism, while nontreponemal tests measure disease activity and treatment response. Neither alone is definitive in every scenario.

Practical steps look like this. First, get a dilated eye exam with a slit lamp from an ophthalmologist, not just a vision check. Second, obtain serology promptly; do not wait for symptom progression. Third, disclose sexual history and HIV status to your clinician, because that information changes the interpretation of borderline results. Fourth, if pregnant, request syphilis testing early and repeat as recommended; congenital syphilis is preventable with timely treatment of the parent. Fifth, if diagnosed, complete the full treatment course and return for follow-up, including repeat eye exams when the ophthalmologist requests them. In the United States, syphilis treatment is generally low-cost or covered publicly at sexual health clinics; costs vary, and confirm with your local clinic.

For clinicians, the thresholds that matter are these: treat any unexplained uveitis as a possible syphilis case until serology comes back, and interpret negative serology in the context of exposure timing. Test for HIV concurrently, since coinfection alters progression. Involve an ophthalmologist early when eye findings are present. Do not diagnose ocular syphilis from a blood test alone; the eye exam must support it. And do not assume treatment of the systemic infection automatically resolves the eye disease without monitoring.

Limitations of the evidence

Much of what clinicians know about ocular syphilis comes from case series and expert consensus rather than large controlled trials. Randomized data on optimal management are sparse, and reported frequencies vary widely across populations and time periods. That variability means any single prevalence figure should be read as a range, not a fixed truth. Diagnostic criteria also vary among guidelines, so cases counted in one study may not be counted in another.

Long-term visual outcomes after treatment are incompletely characterized. Many patients recover substantially, but some retain permanent deficits, particularly when the optic nerve is involved or treatment is delayed. The immune-privileged nature of the eye complicates the question of when the infection is truly eradicated. Researchers continue to study whether organisms can persist in ocular tissue after systemic treatment, and that question remains unsettled. The honest summary: the mechanism is well understood, the risk is real, and the evidence base is thinner than the seriousness of the disease warrants. Screening and prompt testing remain the most reliable tools. For authoritative current guidance, consult the CDC's sexually transmitted infections treatment guidelines and the American Academy of Ophthalmology. (CDC)